M2BPGi for assessing liver fibrosis in patients with hepatitis C treated with direct-acting antivirals.

CONCLUSION: M2BPGi is a reliable marker for the non-invasive assessment and prediction of liver fibrosis regression in patients with CHC who achieved an SVR with DAAs therapy.
PMID: 32550761 [PubMed - in process]

Source: World Journal of Gastroenterology : WJG - June 6, 2020 Category: Gastroenterology Authors: Saleh SA, Salama MM, Alhusseini MM, Mohamed GA Tags: World J Gastroenterol Source Type: research